4.1 Review

Targeted Therapies for Leigh Syndrome: Systematic Review and Steps Towards a 'Treatabolome'

期刊

JOURNAL OF NEUROMUSCULAR DISEASES
卷 8, 期 6, 页码 885-897

出版社

IOS PRESS
DOI: 10.3233/JND-210715

关键词

-

资金

  1. Addenbrookes Charitable Trust [G104114, G100142]
  2. Wellcome Trust [109915/Z/15/Z]
  3. Medical Research Council (UK) [MR/N025 431/1, MR/V009346/1]
  4. European Research Council [309548]
  5. Newton Fund (UK/Turkey) [MR/N027302/1]
  6. Evelyn Trust
  7. Stoneygate Trust
  8. Lily Foundation
  9. MRC [MR/S005021/1]
  10. Horizon 2020 research and innovation program [779257]
  11. NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]

向作者/读者索取更多资源

LS, the most common pediatric clinical presentation of mitochondrial disease, is highly heterogeneous in its clinical phenotype. While historically treatment has been supportive, new therapies are emerging. However, due to the rarity of LS, large-scale interventional studies are limited, with evidence largely remaining in case reports and case series.
Background: Leigh syndrome (LS) is the most frequent paediatric clinical presentation of mitochondrial disease. The clinical phenotype of LS is highly heterogeneous. Though historically the treatment for LS is largely supportive, new treatments are on the horizon. Due to the rarity of LS, large-scale interventional studies are scarce, limiting dissemination of information of therapeutic options to the wider scientific and clinical community. Objective: We conducted a systematic reviewof pharmacological therapies of LS following the guidelines for FAIR-compliant datasets. Methods: We searched for interventional studies within Clincialtrials.gov and European Clinical trials databases. Randomised controlled trials, observational studies, case reports and case series formed part of a wider MEDLINE search. Results: Of the 1,193 studies initially identified, 157 met our inclusion criteria, of which 104 were carried over into our final analysis. Treatments for LS included very few interventional trials using EPI-743 and cysteamine bitartrate. Wider literature searches identified case series and reports of treatments repleting glutathione stores, reduction of oxidative stress and restoration of oxidative phosphorylation. Conclusions: Though interventional randomised controlled trials have begun for LS, the majority of evidence remains in case reports and case series for a number of treatable genes, encoding cofactors or transporter proteins of the mitochondria. Our findings will form part of the international expert-led Solve-RD efforts to assist clinicians initiating treatments in patients with treatable variants of LS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据